Scope of the Study
Sciatica is the name given to pain caused by irritation of the sciatic nerve, anything which irritates this nerve can cause mild to severe pain. Sciatica is usually caused by a compressed nerve in the lower spine.This nerve is the longest and widest nerve in the human body. It runs from the lower back, through the buttocks, and down the legs, ending just below the knee. People who suffer from acute or chronic back pain tend to be more susceptible to Sciatica. The Global Sciatica Treatment market is anticipated to grow at a rapid pace due to rising in safety and success of drug treatment, surge in Geriatrics cases, high growth rate of screening, increase in population, and excruciating pain. Sciatica is triggered by activities like heavy lifting and jerky movements. Over the Counter Medications such as Acetaminophen (Tylenol) and Non-steroidal Anti-Inflammatory Drugs like ibuprofen (Motrin) and Naproxen (Aleve) are being used for the Sciatica Treatment.
The market study is being classified by Type (L4 Nerve Root Sciatica, L5 Nerve Root Sciatica, S1 Nerve Root Sciatica and Others) and major geographies with country level break-up. According to AMA, the Global Sciatica Treatment market is expected to see growth rate of 5.82%
Endo Pharmaceuticals Inc. (United States), AstraZeneca (United Kingdom), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Johnson & Johnson Services, Inc.(United States), Omega Laser Systems Ltd.(Netherlands), Pfizer Inc. (United States) and Sanofi (France) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Neurotech (United Kingdom), Nidd Valley Medical Ltd.(United Kingdom), Omron Healthcare, Inc. (United States) and Sollis Therapeutics (United States).
The Sciatica Treatment market is highly fragmented with Key players focusing on engaging in strategic alliances and collaborations with other players to offer highly differentiated products to cater to the evolving end-user requirements. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Sciatica Treatment market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Sciatica Treatment market by Type, Application and Region.
On the basis of geography, the market of Sciatica Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Drugs, the sub-segment i.e. Anesthetics will boost the Sciatica Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Non-Drug Treatment, the sub-segment i.e. Physiotherapy will boost the Sciatica Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment, the sub-segment i.e. Surgical Treatment will boost the Sciatica Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End user, the sub-segment i.e. Hospitals will boost the Sciatica Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growing Prevalence of Disease Like Sciatica among Patients
- Increasing Geriatric Population in the Past Few Years
- Extra Pressure on Spine Due to Other Health Conditions
- Rising Awareness about Sciatica Treatment
- Development of Injections to treat Sciatica i.e. Clonidine Micropellet Epidural Injections
- High Cost of Treatment
- Complications in Sciatic Surgery such as Risk of Bleeding, Infections etc.
- Development of Medications with Micropellet Technology
- Surgery for the Treatment appears Less Effective in Patients Suffering Chronic Sciatica.
In November 2018, Sollis Therapeutics announced RePRIEVE-CM , Phase 3 trial for a new option is being tested for the treatment i.e. is a micro-pellet based injection which is injected near the inflamed nerve in the spine.It contains a medicine called Clonidine thatís slowly released as the pellet dissolves over time.It reduces the transmission of pain signals from the nerve to the brain. Clonidine is blood pressure medicine thatís being tested for a new use to reduce Sciatic pain.
Key Target AudienceSciatica Manufacturers & Suppliers, Research and Development (R&D) Companies, Hospitals and Clinics, Academic Institutes and Universities, Government & Regulatory Bodies and Health Care Facilities
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase